{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-179447","form_type":"8-K","ticker":"BLCO","cik":"0001860742","company_name":"Bausch & Lomb Corp","filed_at":"2023-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.331967+00:00","generated_at":"2026-06-13T14:22:38.494470+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bausch + Lomb agrees to acquire XIIDRA from Novartis for up to $2.5B","bullets":["Upfront cash $1.75B plus up to $750M in milestones; total consideration up to $2.5B.","XIIDRA generated ~$487M in sales in 2022; patented through 2033.","Acquisition includes libvatrep (Phase 2b) and AcuStream device.","Expected close by end of 2023; immediately accretive; J.P. Morgan committed financing.","B+L expects to return to current leverage within ~24 months post-close."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-179447","json":"https://secwatch.observer/filing/0001193125-23-179447.json","markdown":"https://secwatch.observer/filing/0001193125-23-179447.md","text":"https://secwatch.observer/filing/0001193125-23-179447.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860742/000119312523179447/0001193125-23-179447-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860742/000119312523179447/d493799d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:22:38.494470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}